Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/4/2025 | $28.00 | Outperform | Robert W. Baird |
| 11/18/2024 | $35.00 | Overweight | Stephens |
| 3/14/2024 | $27.00 | Buy | Citigroup |
| 3/7/2024 | $23.00 | Buy | BofA Securities |
| 12/21/2023 | $30.00 | Outperform | Oppenheimer |
| 8/24/2022 | $10.00 → $15.50 | Buy → Neutral | ROTH Capital |
| 2/8/2022 | $9.00 → $12.00 | Buy | HC Wainwright & Co. |
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership of Catalyst’s product portfolioThe transaction is being carried out with the participation of funds managed by BlackstoneCDP Equity approves €1 billion investment in Angelini PharmaItaly remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A. ("Angelini Pharma"), international pharmaceutical company and part of Angelini Industries, announces today the completion of its acquisition of Catalyst Pharmaceuticals, Inc. (
NEW YORK, July 9, 2026 /PRNewswire/ -- Solaris Energy Infrastructure Inc. (NYSE:SEI) will replace Catalyst Pharmaceuticals Inc. (NASD: CPRX) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 15. Angelini Pharma S.p.A. is acquiring Catalyst Pharmaceuticals in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name ActionCompany NameTickerGICS SectorJuly 15, 2026S&P SmallCap 600AdditionSolaris Energy InfrastructureSEIEnergyJuly 15, 2026S&P SmallCap 600DeletionCatalyst PharmaceuticalsCPRXHealth CareABOUT S&P DOW
CORAL GABLES, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced topline results from a two-part Phase 1 clinical study of vamorolone in healthy adult volunteers. The study demonstrated balanced corticosteroid activity with expected cortisol suppression and no evidence of significant immunosuppressive activity at clinical doses. These findings suggest that vamorolone delivers glucocorticoid and anti-inflammatory activity, while avoiding significant
Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00
Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00
Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)
EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
EFFECT - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)
NEW YORK, July 9, 2026 /PRNewswire/ -- Solaris Energy Infrastructure Inc. (NYSE:SEI) will replace Catalyst Pharmaceuticals Inc. (NASD: CPRX) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 15. Angelini Pharma S.p.A. is acquiring Catalyst Pharmaceuticals in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective DateIndex Name ActionCompany NameTickerGICS SectorJuly 15, 2026S&P SmallCap 600AdditionSolaris Energy InfrastructureSEIEnergyJuly 15, 2026S&P SmallCap 600DeletionCatalyst PharmaceuticalsCPRXHealth CareABOUT S&P DOW
CORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of Directors. Dr. Curran is a distinguished pharmaceutical executive with over 25 years of experience spanning strategy, business development, project leadership, and development. Since March 2024, he has served as Managing Partner of Mountainfield Venture Partners, a company-creation firm. He also currently serves as Chief Executive Officer of Timberlyne Therapeutics, a clinical-stage company focused on the development and commercialization of transformational therapies for autoimmune diseases. "Da
CORAL GABLES, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of William (Will) T. Andrews, MD, FACP as Chief Medical Officer. Dr. Andrews will report directly to the Company's President and Chief Executive Officer, Richard J. Daly, and will serve as a member of the Company's executive leadership team. He succeeds Dr. Gary Ingenito, who is retiring after a successful career and will support the transition in a consulting capacity. "We are pleased to welcome Dr. Andrews to Catalyst. In addition to his foundational work in clinical practice in some of the country's most prestigious hospitals, he b
Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded Debt as of March 31, 2026 CORAL GABLES, Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported financial results for the first quarter of 2026 and provided a business update. Financial Highlights For the Three Months Ended March 31, 20262025% Change(In thousands, except per share data) Product Revenue, net$149,343$141,400 5.6%FIRDAPSE Product Revenue, net$98,859$83,731 18.1%AGAMREE Product Revenu
CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, has cancelled its first quarter 2026 earnings conference call and webcast previously scheduled for Tuesday, May 12, 2026, at 8:30 AM ET in light of the pending acquisition by Angelini Pharma S.p.A. announced today. Catalyst will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026, as planned. About Catalyst Pharmaceuticals, Inc.Catalyst Pharmac
CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2026 financial results after the market close on Monday, May 11, 2026. Catalyst's management team will host a conference call and webcast on Tuesday, May 12, 2026, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate:May 12, 2026Time:8:30 AM ETUS/Canada Dial-in